Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aquestive Therapeutics ( (AQST) ) has shared an update.
On September 8, 2025, Aquestive Therapeutics presented an investor presentation at the H.C. Wainwright 27th Annual Global Investor Conference. The presentation highlighted the company’s progress with its product candidates, including Anaphylm and AQST-108, and discussed potential market opportunities and regulatory challenges. The company aims to position Anaphylm as a novel oral administration of epinephrine, pending FDA approval, and anticipates growth in the U.S. epinephrine market. However, the company faces risks related to regulatory approvals, market acceptance, and financial resources.
The most recent analyst rating on (AQST) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Aquestive Therapeutics’ stock score is primarily impacted by its weak financial performance, which poses significant risks. However, strong technical indicators and positive corporate events, including FDA progress and financing for Anaphylm, provide some optimism for future growth. The valuation remains a concern due to ongoing losses.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing products using its proprietary PharmFilm technology. The company primarily targets unmet medical needs with innovative drug delivery solutions, including treatments for epilepsy and anaphylaxis.
Average Trading Volume: 1,616,152
Technical Sentiment Signal: Buy
Current Market Cap: $655.7M
Find detailed analytics on AQST stock on TipRanks’ Stock Analysis page.